CAR T‑Cell Therapy in Rheumatology: Cost and Safety Concerns Temper Enthusiasm
Summary of the Article: Cell therapy for Autoimmune Diseases – Cautious Optimism & Need for Evidence
This article from Healio rheumatology discusses the emerging field of cell therapy for autoimmune diseases, focusing on its potential adn the hurdles to wider adoption. Here’s a breakdown of the key points:
* Promising Early Results: Cell therapy is showing promise in achieving remission for some autoimmune diseases, but it’s a complex and expensive treatment requiring significant paperwork.
* Need for Robust Data: Experts (Khanna and May) emphasize the need for rigorous, randomized controlled trials comparing cell therapy to current standards of care. Long-term data is crucial to assess durability of remission and potential late-term toxicities.
* Long-Term Questions: Key questions remain: Can cell therapy achieve true long-term, drug-free remission? Are there unforeseen long-term side effects?
* Ancient Parallel to Rituximab: The introduction of rituximab is used as a comparison. It took years of real-world data to establish its place in rheumatology.
* Potential for Transformation: If future studies confirm safety, efficacy, and cost-effectiveness, cell therapy could fundamentally change how autoimmune diseases are managed.
* Cautious Optimism: The overall tone is one of cautious optimism,stressing the importance of rigorous evidence before widespread implementation.
Key Individuals & Contact Details:
* Dinesh Khanna, MD, MSc: [email protected] (reports consulting fees/advisory roles with multiple pharmaceutical companies and research support from Amgen & Bristol Myers Squibb)
* Sawyer May: [email protected] (reports no relevant financial disclosures)
Sources:
* Healio Interviews
* Spherix Global Insights report: “Special Topix: Cell Therapy in Rheumatology (U.S.) 2025” (Published October 2025, Accessed November 2025)